|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2200057330 |
|
最近更新日期: Date of Last Refreshed on: |
2022-03-08 15:20:29 |
|
注册时间: Date of Registration: |
2022-03-08 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
请与我们联系上传伦理审批文件。 不同灸量艾灸脾经阳性反应点治疗原发性痛经的疗效观察 |
|
Public title: |
Effect of moxibustion with different amount of moxibustion on the positive reaction point of spleen meridian in treating primary dysmenorrhea |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
窦材“重灸”对原发性痛经患者胞宫微循环的影响 |
|
Scientific title: |
Effect of heavy moxibustion of Doucai on cellular microcirculation in patients with primary dysmenorrhea |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘君 |
研究负责人: |
刘君 |
|
Applicant: |
Jun Liu |
Study leader: |
Jun Liu |
|
申请注册联系人电话: Applicant telephone: |
15532168606 |
研究负责人电话:
Study leader's |
15532168606 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
822053583@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
822053583@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
河北省石家庄市鹿泉区杏苑3号 |
研究负责人通讯地址: |
河北省石家庄市鹿泉区杏苑3号 |
|
Applicant address: |
3 Xingyuan, Luquan District, Shijiazhuang city, Hebei Province |
Study leader's address: |
3 Xingyuan, Luquan District, Shijiazhuang city, Hebei Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
河北中医学院 |
||
|
Applicant's institution: |
Hebei University of Chinese Medicine |
||
|
研究负责人所在单位: |
|
||
|
Affiliation of the Leader: |
|
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
DWLL2020094 |
伦理委员会批件附件: Approved file of Ethical Committee: |
|
|
批准本研究的伦理委员会名称: |
河北中医学院 |
||
|
Name of the ethic committee: |
Hebei University of Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-02-09 00:00:00 | ||
|
伦理委员会联系人: |
未说明 |
||
|
Contact Name of the ethic committee: |
Not stated |
||
|
伦理委员会联系地址: |
河北省石家庄市鹿泉区杏苑3号 |
||
|
Contact Address of the ethic committee: |
3 Xingyuan, Luquan District, Shijiazhuang city, Hebei Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
河北中医学院 |
||||||||||||||||||||||
|
Primary sponsor: |
Hebei University of Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
河北省石家庄市鹿泉区杏苑路3号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
3 Xingyuan, Luquan District, Shijiazhuang city, Hebei Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
河北中医学院省属高校基本科研业务费;河北省中医药管理局项目;国家自然科学基金项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Basic research Funds for Provincial universities of Hebei University of Traditional Chinese Medicine; Hebei Provincial Administration of Traditional Chinese Medicine; National Natural Science Founda |
||||||||||||||||||||||
|
研究疾病: |
原发性痛经 |
||||||||||||||||||||||
|
Target disease: |
primary dysmenorrhea |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
预防性研究 |
||||||||||||||||||||||
|
Study type: |
Prevention |
||||||||||||||||||||||
|
研究所处阶段: |
I期临床试验 | ||||||||||||||||||||||
|
Study phase: |
1 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
比较不同艾灸量艾灸脾经上的阳性反应点治疗原发性痛经的疗效差异,为临床治疗原发性痛经提供最佳艾灸量提供理论依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
Compare different moxibustion moxibustion spleen by the positive point on the amount of the curative effect of treatment of primary dysmenorrhea, provide the best for clinical treatment of primary dysmenorrhea moxibustion quantity to provide theoretical basis |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
①符合原发性痛经的诊断标准; |
||||||||||||||||||||||
|
Inclusion criteria |
①Meet the diagnostic criteria of primary dysmenorrhea; |
||||||||||||||||||||||
|
排除标准: |
①经B超及妇科检查,证实由于子宫内膜异位症、盆腔炎、子宫腺肌病等疾病或其他因素引起的继发性痛经; |
||||||||||||||||||||||
|
Exclusion criteria: |
①Through B ultrasonic and gynecological examination, confirmed as a result of endometriosis pelvic inflammation adenomyopathy and other diseases or other factors caused by secondary dysmenorrhea; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-01-01 00:00:00至 To 2023-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-03-01 00:00:00 至 To 2022-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由操作者采用随机数字表法将患者随机分为3组 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Patients were randomly divided into 3 groups by the operator using random number table method |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2023年12月1日;采用CRF 表形式 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
December 1, 2023; CRF table format |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病历记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |